Senior Regulatory Affairs Manager
ORIC Pharmaceuticals
Senior Regulatory Affairs Manager
ORIC Pharmaceuticals
Clinical-stage oncology company targeting resistance
We are seeking an experienced Regulatory Affairs professional to join our team and help advance the clinical development of oncology products at ORIC. In this role, you will collaborate closely with colleagues across regulatory operations, quality, CMC, nonclinical and clinical functions to support high-quality, timely regulatory submissions. The ideal candidate is a proactive team player who thrives in cross-functional environments, communicates effectively, and can balance strategic thinking with strong execution.
Essential duties and responsibilities include the following. Other duties may be assigned.
Perform all duties in keeping with the Company’s core values, policies and all applicable regulations.
The anticipated salary range for candidates is between $175,000-$200,000 in South San Francisco. The final rate offered to a successful candidate will be dependent on several factors that may include but are not limited to the title, type and length of experience within the job, type and length of experience within the industry, education, etc. This position is not eligible for H-1B visa sponsorship.
ORIC Pharmaceuticals, Inc. is an equal opportunity employer. ORIC does not discriminate based on race, color, religion, gender, sexual orientation, gender identity, age, national origin, disability status, protected veteran status, or any other legally protected characteristic.
Salary Range : SD:$153K/$170K/$194K_SSF $160K/$181K/$210K
Clinical-stage oncology company targeting resistance
ORIC Pharmaceuticals is a clinical-stage cancer company focused on overcoming how cancers resist treatment. Its therapies aim to restore patients’ response to existing treatments by targeting resistance mechanisms. Lead programs include rinzimetostat (ORIC-944), an allosteric inhibitor of the PRC2 complex designed for prostate cancer, and enozertinib (ORIC-114), a brain-penetrant inhibitor that targets EGFR exon 20 and HER2 exon 20 mutations in non-small cell lung cancer. Early work continues on other resistance mechanisms across solid tumors. Unlike some competitors, ORIC concentrates specifically on breaking or bypassing resistance to current therapies, based on research from Memorial Sloan Kettering Cancer Center and brought to Nasdaq-listed status in 2020. Its goal is to improve how well existing cancer treatments work for patients by keeping cancer from outsmarting them.
Explore more opportunities at ORIC Pharmaceuticals